FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues

Monkeypox and Cancer: a Pan-cancer Based Multi-omics Analysis and Single Cell Sequencing Analysis-Experimental Studies

Colorectal cancer tissue sections were obtained according to the inclusion criteria. The formalin was used to immersed all cancer specimens. And tissues were cut to 5 μm thickness and placed on glass slides before staining. Endogenous peroxidase activity was inhibited and blocked by de-paraffinizing, rehydrating, and using 5% bovine serum albumin at 37ºC for 30 min. The treated sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Study Overview

• Status: Recruiting
• Conditions: Colorectal Cancer; Monkey Pox
• Intervention / Treatment: Diagnostic test: Immunohistochemical staining with anti-FOS

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Phase 2; Phase 3

Contacts and Locations

• Study Contact: Name: Xiaoliang Huang, Dr.; Phone Number: 0086-13617713823; Email: xiaoliang@sr.gxmu.edu.cn

Study Locations

• China
  • Guangxi
    • Nanning, Guangxi, China
      • Recruiting
      • Guangxi Medical University Cancer Hospital
      • Contact: Xiangliang Huang, Dr.; Phone Number: +8613617713823; Email: xiaoliang@sr.gxmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• (a) patients with histologically confirmed CRC (b) patients who underwent resection of the primary tumor (c) patients at first visit who had not received treatment before blood testing.

Exclusion Criteria:

• (a) familial adenomatous polyposis or hereditary colon cancer (b) no signs of clinical infection, such as fever, on the day of blood collection; And (c) patients with multiple primary tumors during hospitalization.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Test group-stained by FOS antibody; Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.

Diagnostic test: Immunohistochemical staining with anti-FOS; The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Original survival	Time from the start of the study to death from any cause. For subjects who were lost to follow-up before death, the time of last follow-up was calculated as the time of death.	Participants were followed up for 3 years, including outpatient follow-up and telephone follow-up.

Collaborators and Investigators

• Sponsor: xiaoliang Huang

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2020
• Primary Completion (Anticipated): January 1, 2025
• Study Completion (Anticipated): January 1, 2025

Study Registration Dates

• First Submitted: January 16, 2023
• First Submitted That Met QC Criteria: January 25, 2023
• First Posted (Estimate): January 26, 2023

Study Record Updates

• Last Update Posted (Estimate): January 26, 2023
• Last Update Submitted That Met QC Criteria: January 25, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: Tumor microenvironment; Differential expression of gene; Immunohistochemical staining
• Additional Relevant MeSH Terms: Digestive System Diseases; Virus Diseases; Infections; Neoplasms; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; DNA Virus Infections; Intestinal Neoplasms; Rectal Diseases; Poxviridae Infections; Colorectal Neoplasms; Monkeypox
• Other Study ID Numbers: KY-2020-305

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No